Could a simpler surgery be safer for aggressive uterine cancer?

NCT ID NCT06900582

Not yet recruiting Disease control Sponsor: University Hospital, Strasbourg, France Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two surgical approaches for women with early-stage, high-risk endometrial cancer that has a p53 gene mutation. One group will get the standard extensive lymph node removal, while the other gets a less invasive sentinel node biopsy. The goal is to see if the simpler procedure is just as good at preventing cancer from coming back, with fewer side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sentinel lymph node mapping (a less invasive surgical procedure to check for cancer spread)
What this could lead to: If successful, this could show that a less invasive surgery is safe for women with this aggressive type of endometrial cancer, reducing side effects like lymphedema.
What could go wrong: This is a relatively early-stage trial (Phase NA) with 374 participants. The less invasive approach might not catch all cancer spread, potentially leading to higher recurrence rates.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial cancer endometrium neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ENDOMETRIAL CANCER GENE, P53 LYMPHADENECTOMY SENTINEL LYMPH NODE BIOPSY (SLNB)

More trials for these conditions

Other studies related to the condition(s) this trial covers.